Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 12/20 | 0.60 |
| ▸ | ADRA2B | P18089 | 10/20 | 0.60 |
| ▸ | ADRA2C | P18825 | 10/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | NISCH | Q9Y2I1 | 3/20 | 0.60 |
| ▸ | HRH2 | P25021 | 2/20 | 0.60 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.57 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.57 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6054567 | 0.80 | ADRA2A (0.61) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| SCHEMBL6964252 | 0.76 | ADRA2A (0.51) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| SCHEMBL11178090 | 0.76 | ADRA2A (0.60) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL60334 | 0.75 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL20769844 | 0.75 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| SCHEMBL11197434 | 0.75 | ADRA2A (0.58) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| SCHEMBL11193123 | 0.75 | ADRA2A (0.58) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL6472652 | 0.74 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL41199 | 0.74 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Clonidine SCHEMBL5983 | 0.74 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019021-B2 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-03-28 | — | — | US | disclosed |
| US-6858594-B2 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG. (DE) | 2005-02-22 | — | — | US | disclosed |
| US-20040198796-A1 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-10-07 | — | — | US | disclosed |
| US-20030114425-A1 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-06-19 | — | — | US | disclosed |
| EP-1285653-A1 | Use of alpha-1L agonists in the treatment of incontinence | Boehringer Ingelheim Pharma KG (DE) | 2003-02-26 | — | — | EP | disclosed |
| US-6268389-B1 | Treatment of urinary incontinence by administration of α1L-adrenoceptor agonists | BOEHRINGER INGELHEIM KG (DE) | 2001-07-31 | — | — | US | disclosed |
| EP-0821585-A1 | USE OF $g(a) 1L? AGONISTS IN THE TREATMENT OF INCONTINENCE | BOEHRINGER INGELHEIM KG (DE) | 1998-02-04 | — | — | EP | disclosed |
| WO-1996032939-A1 | USE OF α1L AGONISTS IN THE TREATMENT OF INCONTINENCE | BOEHRINGER INGELHEIM KG (DE) | 1996-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114425-A1 | Compounds and methods for treating urinary incontinence | PDE3A, PDE3B, PDE2A | ADRA2A 16/4885ADRA2B 14/4885ADRA2C 12/4885 |
| US-20040198796-A1 | Compounds and methods for treating urinary incontinence | REN, ARG1, RXFP1 | ADRA2A 115/4885ADRA2B 99/4885ADRA2C 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.